Research Article
Retrospective Analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients Treated with Antiemetics
Takanori Goi1*, Toshiyuki Nakazawa1, Youhei Kimura1, Katsuji Sawai1, Mitsuhiro Morikawa1, Kanji Katayama1, Akiko Momota2, Hiroko Kubo2, Kyouhei Watanabe3, Mikio Masada3 and Akio Yamaguchi11First Department of Surgery, University of Fukui, 23-3, Eiheiji-cho, Yoshida-gun, Fukui, Japan
2Ambulatory Therapy Center, University of Fukui, 23-3, Eiheiji-cho, Yoshida-gun, Fukui, Japan
3Department of Pharmacy, University of Fukui, 23-3, Eiheiji-cho, Yoshida-gun, Fukui, Japan
- *Corresponding Author:
- Takanori Goi
First Department of Surgery, University of Fukui
23-3, Eiheiji-cho, Yoshida-gun, Fukui, Japan
Tel: 81-776-61-3111
Fax: 81-776-61-8113
E-mail: tgoi@u-fukui.ac.jp
Received date: May 11, 2012; Accepted date: August 28, 2012; Published date: August 30, 2012
Citation: Goi T, Nakazawa T, Kimura Y, Sawai K, Morikawa M, et al. (2012) Retrospective Analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients Treated with Antiemetics. J Palliative Care Med S1:006. doi: 10.4172/2165-7386.S1-006
Copyright: © 2012 Goi T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and
Abstract
Purpose: The aim of this retrospective study was to clarify the effect of the antiemetics for chemotherapy-induced nausea and vomiting associated with FOLFOX chemotherapy.
Methods: Fifty patients were given FOLFOX as chemotherapy for colorectal cancer, and granisetron were used as first-line antiemetics. The severity of CINV was evaluated using (1) questioning, (2) Common Terminology Criteria for Adverse Events version 4.0, and (3) Multinational Association of supportive care in cancer method for patient self�assessment. When a patient indicated that another antiemetic was desired, granisetron was switched to palonosetron.
Results: Forty two patients did not express a desire for another antiemetic, but eight patients expressed a desire for it. They were evaluated as Grade 2 according to the CTCAE 4.0. The MAT method identified a score of 6 points or more. Granisetron was switched to palonosetron as a second-line antiemetic. The severity of CINV decreased to Grade 1 or less, while the MAT method score decreased to 0 points in 3 patients and ≤ 4 points in 5 patients. None of the 8 patients expressed a desire for another antiemetic.
Conclusion: Granisetron/palonosetron can be thought to have improved the patients’ QOL, relieved their anxiety, and contributed to continuation of the chemotherapy.
